OTLKNasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing ophthalmic therapies, centered on ONS-5010/LYTENAVA (bevacizumab gamma). The company’s business spans clinical development, regulatory approvals, manufacturing, and commercial distribution of its eye-disease product in selected international markets.

Kysy yhtiöstä
Liikevaihto1,4milj. USD
Liikevoitto (EBIT)−67,1milj. USD
+6,5 %v/v
EBIT-marginaali−4 744,3%
Nettotulos−62,4milj. USD
+17,2 %v/v
Vapaa kassavirta−51,8milj. USD
+24,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−80−60−40−20020milj. USD2020: EBIT −37 milj. USD20202021: EBIT −52 milj. USD20212022: EBIT −63 milj. USD20222023: EBIT −53 milj. USD20232024: EBIT −72 milj. USD20242025: 1,4 milj. USD2025: EBIT −67 milj. USD20251,4−67
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Commercial ophthalmic biologic100 %

LYTENAVA sales to wholesalers/distributors for use in eye-care settings.

Clinical and regulatory development0 %

Development work for ONS-5010/LYTENAVA and related approvals.

Manufacturing and supply chain0 %

Contract manufacturing, fill-finish, and syringe supply for the product.

Asiakkaat

The company sells LYTENAVA to pharmaceutical wholesalers and distributors, which then supply clinics, hospitals, and pharmacies. Its end demand is tied to ophthalmology treatment settings, especially for wet age-related macular degeneration. In addition to commercial buyers, the business depends on regulators, contract manufacturers, and clinical partners to advance and supply the product.

Pharmaceutical wholesalers/distributors

Buy LYTENAVA in bulk and distribute it to healthcare providers and pharmacies.

Clinics and hospitals

Use the product in ophthalmology care for wet AMD patients.

Pharmacies

Receive product through distribution channels for patient access.

Regulatory authorities

Approve product labeling, commercialization, and market access by geography.

Strategia

The company’s strategy is to commercialize LYTENAVA in markets where it has regulatory authorization while pursuing additional licensing and marketing arrangements to extend reach. It also relies on external financing and partnerships to support development, manufacturing scale-up, and market expansion.

Expand commercial access for LYTENAVALyhyt aikaväli

Revenue depends on converting regulatory approvals into market sales.

Build partnership and licensing channelsKeskipitkä aikaväli

Partnerships can extend geographic reach and provide funding support.

Secure supply chain and manufacturing capacityLyhyt aikaväli

Commercial execution depends on reliable cGMP manufacturing and fill-finish.

Maantiede

Outlook Therapeutics is headquartered in Iselin, New Jersey and manufactures ONS-5010/LYTENAVA in the United States. Commercial activity has been centered in Europe, with the company noting sales in Germany and the UK and pursuing additional licensing opportunities in the Southern Hemisphere where approvals may rely on its European authorization.

Riskit

The business is exposed to financing risk, regulatory risk, and execution risk because it depends on a single commercial product and ongoing development work. It also faces supply-chain, intellectual property, and clinical-trial risks typical of biopharmaceutical companies, where delays or setbacks can materially affect commercialization timelines and market access.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Going-concern and capital shortfall1Regulatory approval and clinical development delays2Single-product concentration3Manufacturing and supply-chain disruption4Intellectual property loss or challenge5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going-concern and capital shortfallVaikutus: KriittinenTodennäköisyys: Korkea

    The company needs additional financing to fund operations and commercialization.

    Kohdistuu: Corporate-wide

  2. Regulatory approval and clinical development delaysVaikutus: KorkeaTodennäköisyys: Korkea

    The product depends on approvals and may require additional studies or CMC data.

    Kohdistuu: ONS-5010/LYTENAVA

  3. Single-product concentrationVaikutus: KorkeaTodennäköisyys: Korkea

    Revenue and strategic value are tied largely to one ophthalmic product.

    Kohdistuu: LYTENAVA

  4. Manufacturing and supply-chain disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on contract manufacturers and single-source suppliers.

    KohdistuuDrug substanceFill-finishSyringe supply
  5. Intellectual property loss or challengeVaikutus: KorkeaTodennäköisyys: Matala

    Failure to secure or maintain rights could force abandonment of programs.

    Kohdistuu: Product candidates and commercialization rights

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition at point of delivery

Revenue is recorded when product is physically delivered to customers, affecting timing.

Vaikutus: Shipment timing can shift revenue between quarters.

Fair value of promissory notes

The company records gains or losses from changes in note fair value.

Vaikutus: Can materially affect net income without changing cash flow.

Warrant liability remeasurement

Derivative-like warrant liabilities are revalued each period.

Vaikutus: Creates non-cash earnings volatility.

Going-concern and liquidity assumptions

Management must assess whether available cash supports operations for 12 months.

Vaikutus: Affects disclosure and investor assessment of survival risk.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Ocugen, Inc.

OCGN · Biological Products, (No Diagnostic Substances)

Ocular Therapeutix, Inc

OCUL · Pharmaceutical Preparations

OS Therapies Inc

OSTX · Pharmaceutical Preparations

Perspective Therapeutics, Inc.

CATX · Pharmaceutical Preparations

Iterum Therapeutics plc

ITRMF · Pharmaceutical Preparations

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Outlook Therapeutics, Inc. (Nasdaq) – Biological Products, (No Diagnostic Subs | Analyysi – Clarifo